Navigation Links
Maxwell Biotech Venture Fund's Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
Date:4/4/2017

MOSCOW, April 4, 2017 /PRNewswire/ --

Hepatera LLC and its development partner MYR GmbH today announced the completion of recruitment for MYR 202 and 203 clinical trials, a Phase 2b program investigating Myrcudex B in chronic hepatitis delta infection. 180 subjects have been enrolled in 20 centers in Russia and Germany.

Maxwell Biotech Venture Fund Logo
Maxwell Biotech Venture Fund Logo

     (Logo: http://photos.prnewswire.com/prnh/20140213/668442-b)

"We are pleased to participate in the MYR 202 trial and look forward to results of this world's largest study in this severe unmet medical need," said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR's Clinical Advisory Board.

"We are thankful for the enthusiastic collaboration of the participating centers, which has allowed us to meet the recruitment goals within the planed period," commented Dr. Dmitry Popov, Managing Partner of Maxwell Biotech Fund. "The interim results of MYR 202 will be available by the end of 2017."

About Myrcludex B 

Myrcludex B is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver.

About Hepatera 

The main activity of Hepatera Ltd. is the development of safe and effective drugs for the treatment of liver diseases for the Russian market. Myrcludex B is developed by the company in cooperation with the biotechnology company MYR, GmbH (Germany).

About MYR GmbH 

MYR GmbH is a clinical stage biotechnology company focused on drugs for treatment of chronic hepatitis B and D virus infections. The company was founded in 2010 and is based in Burgwedel, Germany. Myr GmbH is received investments from Maxwell Biotech Venture Fund and High-Tech Gründerfonds (HTGF).

About Maxwell Biotech Venture Fund 

Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The Fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development; four thereof are in Phase 2.


'/>"/>
SOURCE Maxwell Biotech Venture Fund
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Start of Phase 2b Clinical Trial of Myrcludex B
2. Separation Systems for Commercial Biotechnology
3. Research Reports Coverage on Biotech Stocks -- Agenus, Intrexon, Progenics Pharma, and Concordia
4. Agricultural Biotechnology - Emerging Technologies & Global Markets - Driving Forces, Market Applications, Industry Structure & Competitive Dynamics - Research and Markets
5. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
6. On World Tuberculosis Day 2017, American/Russian biotech partnership announces positive trial results for a new treatment of TB
7. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
8. Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus
9. Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care
10. Three Day Biotechnology for the Non-Biotechnologist Course (London, United Kingdom - September 27-28-29, 2017) - Research and Markets
11. Festo Introduces at Interphex a New Family of Sanitary/Automated Ball, Angle Seat, and Pinch Valves for the Pharma and Biotech Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2018)... ... November 06, 2018 , ... ... for clinical trial data collection and management. TrialKit ™, an eClinical platform, ... generation devices can quickly and easily sign in to the app via facial ...
(Date:11/5/2018)... (PRWEB) , ... November 05, 2018 , ... ... and telemedicine company backed by Siemens Healthineers and several healthcare VC firms announces ... radiology solution and making a history by purchasing tokens and obtaining its first ...
(Date:11/5/2018)... ... November 05, 2018 , ... 2Blades has ... Activator Like (TAL) effector code technology for applications in advancing research in epigenetic ... in plants. Since its discovery in 2009, the efficacy of TAL effector-based DNA targeting ...
(Date:11/3/2018)... ... November 01, 2018 , ... Triangle Insights Group, a premier ... one of the fastest-growing private companies in the United States, appearing on this year’s ... private companies based on percentage revenue growth over the previous three years. , ...
Breaking Biology Technology:
(Date:12/13/2018)... ... December 12, 2018 , ... NDA ... of the firm’s prominent Expert Consultants, was recently honored by the American Association ... who are working in pharmaceutical science, technology, engineering, or education and whose contributions ...
(Date:12/13/2018)... ... December 13, 2018 , ... ... must-see documentary entitled “What Researchers Need to Know about Antibody Manufacturing” . ... Science Research series. The goal of this film is to educate scientists about ...
(Date:12/5/2018)... ... 2018 , ... Surgical Theater brings familial patient engagement to ... 2018 at booth #312. AANS/CNS provides Pediatric Neurosurgeons an opportunity to experience Precision ... from the consultation, to surgical planning, and into the operating room. , ...
Breaking Biology News(10 mins):